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Abstract
Background: Pseudomonas aeruginosa is one of the most common Gram-negative pathogen causing nosocomial infection world-
wide. The emergence of multi-drug resistant strains has become a major clinical concern in recent years. Resistance-nodulation-cell
division (RND) family eﬄux pumps play an important role in the development of multidrug resistance in P. aeruginosa.
Objectives: The aims of the present study were to evaluate the antimicrobial susceptibility against carbapenems used and to eval-
uate the gene expression of two resistance nodulation cell division-type eﬄux pump systems (MexB and MexY ) among carbapenem
non-susceptible P. aeruginosa.
Methods: A total of 256 non-repetitive P. aeruginosa were collected from the different clinical samples of patients admitted in Qazvin
and Tehran educational hospitals. Antimicrobial susceptibility testing was performed by standard Kirby-Bauer method. The expres-
sion of MexB and MexY genes was assessed by quantitative real-time polymerase chain reaction (qRT-PCR).
Results: In total, 107 (41.8%) isolates were non-susceptible to imipenem and/or meropenem. All carbapenem non-susceptible isolates
were positive for the presence of MexB and MexY genes. The expression of MexB (P value = 0.004) and MexY (P value = 0.001) genes
was significantly increased, compared to standard carbapenem sensitive strains.
Conclusions: The findings of the present study showed the considerable presence of carbapenem resistance among the clinical
isolates of P. aeruginosa. The overexpression of MexB and MexY genes is also established among these resistant isolates collected
from studied hospitals in Iran.
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1. Background
Pseudomonas aeruginosa is an opportunistic pathogen
that has been known as one of the significant pathogen
contributing in nosocomial infection worldwide (1). This
organism is able to cause severe infection in patients,
most notably those with cystic fibrosis or hospitalized in
intensive care units (2, 3). The extensive use of broad-
spectrum antibiotics contributes to the emergence of mul-
tidrug resistant P. aeruginosa (MDRPA). MDR in P. aerug-
inosa is defined as the resistance to three or four of an-
tibiotic classes includingβ-lactams, aminoglycosides, and
fluoroquinolones (4). Carbapenems such as meropenem
and imipenem are classified as β-lactam antibiotics that
are routinely used as therapy for P. aeruginosa (5). These
antibiotics have a broad spectrum of activity but in re-
cent years, the development of carbapenems resistance
has been showed among P. aeruginosa isolates (6).
P. aeruginosa is resistant to carbapenem through sev-
eral mechanisms: first, diminished cell-wall permeabil-
ity; second, the constitutive expression of various ef-
flux pumps; and third, the production of antibiotic-
inactivating-hydrolyzing enzymes (7).
Bacterial antimicrobial eﬄux transporters have gen-
erally been classified according to amino acid sequence
homology. Five superfamilies have been identified in-
cluding the major facilitator superfamily (MFS) (8), the
ATP-binding cassette family (9), the resistance-nodulation-
division (RND) family (10, 11), the small multidrug resis-
tance (SMR) protein family (12), and multidrug and toxic
compound extrusion (MATE) family (13).
RND family is the most common multidrug eﬄux
systems in clinical Gram-negative bacteria especially in
P. aeruginosa (10). Several RND-type multidrug eﬄux
systems in P. aeruginosa have been identified, among
those MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-
OprM are reported to be significant determinants among
multidrug resistant clinical isolates (14). MexAB-OprM
and MexXY-OprM pumps show natural resistance against
antimicrobial and disinfectant compounds. MexAB-
OprM system provides resistance to a broad spectrum
of antibiotics including tetracycline, chloramphenicol,
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quinolones, trimethoprim, and most β-lactams and
MexXY-OprM contributes to the low intrinsic susceptibil-
ity to aminoglycosides, tetracycline, and erythromycin
(15).
The aims of this study were to determine the antimi-
crobial susceptibility against carbapenem among P. aerug-
inosa isolated from patients in hospitals of Tehran and
Qazvin provinces, and also to evaluate the existence and ex-
pression of MexB and MexY genes as important factors of
drug resistance among these isolates.
2. Methods
2.1. Study Design and Identification
A total of 256 non-repetitive P. aeruginosa isolates were
collected from the various clinical samples of patients
admitted in educational hospitals of Qazvin and Tehran.
These bacterial isolates were collected from February, 2012
until December, 2014. The study was approved by the ethics
committee of Qazvin University of Medical Sciences (code
IR.QUMS.REC.1394.147). The isolate identification was done
by standard laboratory methods including bacteriologic
and biochemical tests such as Gram stain, oxidase test,
growth on cetrimide agar medium (Liofilchem, Italy), the
ability to grow at 42°C, O/F (Oxidation-Fermentation) test,
and pigment production. The bacterial isolates were ob-
tained from different clinical specimens including urine,
sputum, wound, tracheal aspirate, blood, and bronco alve-
olar lavage.
2.2. Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was performed by
Kirby-Bauer disc diffusion method against imipenem (10
µg), meropenem (10 µg) (Mast Diagnostics Group Ltd,
Merseyside, UK) according to the CLSI guideline (16). For
quality control in antimicrobial susceptibility testing, P.
aeruginosa ATCC 27853 was used.
2.3. Detection of Mexy and Mexb Genes by PCR Assay
PCR assay was performed for carbapenem non-
susceptible P. aeruginosa isolates for the detection of
MexY and MexB genes using specific primers (Table 1).
DNA extraction was performed using a commercial kit
(Bioneer, South Korea) according to the manufacturer’s
instruction. PCR amplifications were performed in a ther-
mocycler (Applied Biosystems, USA) as follows: 7 minute at
95°C and 35 cycles of 1 minute at 95°C, 1 minute at specific
annealing temperature and 1 minute at 72°C, followed
by a final extension at 72°C for 10 minute. Amplification
reactions were prepared in a total volume of 25 µL (24 µL
of PCR master mix plus 1µL of template DNA), 10 mM dNTP
mix at a final concentration of 0.2 mM, 2.0 U of Taq DNA
polymerase, 50 mM MgCl2 at a final concentration of 1.5
mM, 1 µM of each primer, and 1X PCR buffer. PCR products
were visualized on ethidium-stained 1% agarose gels in gel
documentation system (UVtec, UK).
Table 1. Primers Used in This Study
Genes Sequence (5’→
3’)
Size, bp References
MexY
F: CCGCTACAACG-
GCTATCCCT
246
(17)
R: AGCGGGATC-
GACCAGCTTTC
MexB
F: GTGTTCG-
GCTCGCAGTACTC
244
(17)
R: AAC-
CGTCGGGATTGAC-
CTTG
2.4. RNA Extraction and Synthesis of cDNA
For the extraction of total RNA, P. aeruginosa isolates
were cultured in 1.5 mL LB broth, left in a shaker incubator
(180 rpm) at 37°C for 18 - 24 hours. Plates were incubated
overnight at 37°C and then were centrifuged (8,000 rpm) at
4°C for 7 minutes. For the extraction of total RNA, the sedi-
ment was used using a commercial kit (RNeasy kit, Qiagen,
Germany), according to the manufacturer’s protocol.
To eliminate the genomic DNA, a commercial RNase-
free DNase kit (DNase, RNase-free, Fermentas, Thermo Sci-
entific, USA) was used according to the manufacturer’s pro-
tocol. To prepare cDNA, 5µL of extracted RNA was added to
15µL deionized water and converted to cDNA in a total vol-
ume of 20µL using a commercial kit (cDNA kit, BioNeer Pa-
cific, Australia) according to the manufacturer’s protocol.
Electrophoresis on agarose gel was performed for quality
and quantity of extracted RNA. In order to determine MexY
and MexB gene expression, real-time PCR was performed
using a commercial kit (SYBR® Green2X Master Mix; Ap-
plied Biosystems, USA) on an Applied Biosystems 7,500
real-time PCR (Fort Collins, Colorado, USA). Briefly, 0.5 µL
of each primer, 5 µL cDNA, 4 µL deionized water, and 10 µL
Master Mix were added to a standard 96-well microplate
(Applied Biosystems; USA). PCR reactions were performed
in final volume of 20 µL for 45 cycles. Melting curve was
drawn to evaluate the specificity of PCR reaction, followed
by electrophoresis of PCR products on 2% agarose gel. The
specific primers to evaluate the changes of MexY and MexB
genes expression in carbapenem non-susceptible P. aerugi-
nosa isolates are shown in Table 1 (17). For normalization of
target gene expression levels, the housekeeping rpoD gene
was used as internal standard control and the standard P.
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aeruginosa strain (ATCC 27853) for comparative evaluation
of the MexY and MexB genes.
2.5. Statistical Analysis
One-Sample Student’s t-test was used to compare the
mean values of quantitative variables; comparison of MexY
and MexB genes expression obtained for carbapenem non-
susceptible isolates with those of obtained for standard
(control) P. aeruginosa PAO1 (ATCC 27853) strain.
3. Results
The results of antimicrobial susceptibility testing indi-
cated that 13 (5.1%) and 3 (1.2%) isolates were non-susceptible
to meropenem and imipenem, respectively. Ninety-one
(35.5%) isolates were non-susceptible to imipenem and
meropenem, simultaneously. In total, 107 (41.8%) isolates
were non-susceptible to imipenem and/or meropenem.
PCR assay showed that all carbapenem non-susceptible
isolates were positive for the presence of MexY and MexB
genes. In total, qRT-PCR showed different expressions in
different clinical isolates. The expression of MexB (P value
= 0.004) and MexY (P value = 0.001) genes was signifi-
cantly increased, compared to standard carbapenem sen-
sitive strains.
4. Discussion
Resistance to multiple antibiotics in P. aeruginosa is
one of the most serious therapeutic challenges for treat-
ment of both community-acquired and nosocomial infec-
tions (1). Treatment of MDRPA is difficult due to limited
choice of antibiotics because this bacteria is capable of
showing resistance to antibiotics by intrinsic and acquired
resistance ways (4). The constitutive expression of eﬄux
pumps such as MexAB-OprM and MexXY-OprM have an im-
portant role in resistance to several classes of antibiotics
(14). Carbapenems such as imipenem and meropenem are
frequently used as the last therapeutic strategy against the
infections caused by MDRPA. However, the emergence of
carbapenem resistant isolates has become a serious clini-
cal concern around the world (6).
In the present study, resistance to imipenem and/or
meropenem was 41.8% which is higher than the results of
previous studies have been reported by Shahcheraghi et al.
(12.4%) and Japoni et al. (30%) in Iran (18, 19), but lower than
that found in two studies carried out by Sepehriseresht et
al. (56%) and Khosravi et al. (41%) in burn patients in Iran
(20, 21). It seems, the variable susceptibility rate of car-
bapenems among P. aeruginosa isolates in different studies
could be due to varied antibiotic usage profiles in different
geographic regions.
In the present study, all isolates were positive for the
presence of MexY and MexB genes; the data showed the
presence of these eﬄux pumps are common in P. aerugi-
nosa. Our study also showed that overexpression of MexB
and MexY genes is one of the important mechanisms to
resist against carbapenems. In a similar study from Iran,
Arabestani et al. showed that all clinical isolates of P.
aeruginosa were positive for the presence of MexAB-OprM
genes but a different expression of MexR, OprD, and MexB
genes was observed in resistant isolates (22). Masuda and
coworkers showed that MexXY contributes to the intrin-
sic resistance to antibacterial drugs (23). Dumas et al. re-
ported that MexX and MexY genes were induced 8 to 12
times in the presence of tetracycline and mexC/oprJ and
mexE/oprN gene expression levels were increased 30- to
250-fold and 100- to 760-fold in mutant isolates, respec-
tively (24). Hocquet et al. in two French teaching hospi-
tals showed the major role of MexXY-OprM in the devel-
opment of cefepime resistance among clinical strains of
P. aeruginosa (25). Terzi and coworkers in Turkey showed
that MexB was overexpressed in 15 of 22 and MexY in 19 of
22 of multidrug resistant P. aeruginosa isolates. They, also,
reported that transcription of MexB was directly correlated
with meropenem resistance in the majority of their iso-
lates (26).
4.1. Conclusions
Findings of the present study showed the considerable
presence of carbapenem resistance among the clinical iso-
lates of P. aeruginosa. Overexpression of MexB and MexY
genes is also established among these resistant isolates
which highlights the need for establishing suitable strate-
gies to effectively treat patients and prevent the further dis-
tribution of these resistant organisms in our hospitals.
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